Oxford Nanopore Technologies plc: Business Overview, Financials & Competitive Analysis
Oxford Nanopore Technologies plc scores 6/10 on the AskCyborg Cyborg Score (Mixed). High-growth molecular sequencing platform approaching profitability with strong gross margins, but execution risk on 2027 breakeven target amid competitive pressures and geopolitical headwinds. Financial performance is held back primarily by weak financial performance—large ongoing losses and continued cash burn—despite improving revenue growth and solid gross margins. Offsetting factors.
What is Oxford Nanopore Technologies plc's industry? Oxford Nanopore Technologies plc (nanoporetech.com) operates in DNA Sequencing. AskCyborg classifies Oxford Nanopore Technologies plc under DNA Sequencing in its company registry.
Oxford Nanopore Technologies develops, manufactures, and commercializes DNA/RNA sequencing technology that provides rich data, is fast, accessible, and easy to use, allowing real-time analysis of DNA or RNA. The platf...
Cyborg Score thesis
High-growth molecular sequencing platform approaching profitability with strong gross margins, but execution risk on 2027...
Read the full analyst-debate transcript →Get the Latest Oxford Nanopore Technologies plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOxford Nanopore Technologies plc Overview
Pro stress-test →Oxford Nanopore Technologies develops, manufactures, and commercializes DNA/RNA sequencing technology that provides rich data, is fast, accessible, and easy to use, allowing real-time analysis of DNA or RNA. The platform is being developed for the analysis of proteins and metabolites in addition to DNA/RNA sequencing. Its platforms are used in more than 125 countries across healthcare, research, and agriculture.
Strategic Profile
Pro stress-test →FY25 revenue rose 24.2% to £223.9m, with gross margin guidance at approximately 62%. Co-founder Gordon Sanghera departed as chief executive officer, with Francis Van Parys taking over as CEO. The company targets adjusted EBITDA breakeven in FY27, with strong progress in H1 2026.
Competitive Landscape
Pro stress-test →Competitors include Pacific BioSciences, Illumina, OncoDNA, Quantapore, and Vizgen. Oxford Nanopore differentiates through its portable, real-time sequencing platforms and expanding platform breadth across proteins and metabolites. The company competes primarily on speed, accessibility, and platform versatility rather than raw throughput.
Industry Context
Oxford Nanopore Technologies plc operates in DNA Sequencing.
Key facts
Founded: 2005 · Headquarters: Oxford, United Kingdom · Employees: 1,300 · Revenue: £223.9M for FY2025 (approximately $280M at current rates) · Market cap: $1.57B